These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12435059)

  • 1. Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxic component.
    Mahmut N; Inoue K; Fujinaga Y; Arimitsu H; Sakaguchi Y; Hughes L; Hirst R; Murphy T; Tsuji T; Watanabe T; Ohyama T; Karasawa T; Nakamura S; Yokota K; Oguma K
    J Med Microbiol; 2002 Oct; 51(10):813-820. PubMed ID: 12435059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.
    Held DM; Shurtleff AC; Fields S; Green C; Fong J; Jones RG; Sesardic D; Buelow R; Burke RL
    Clin Vaccine Immunol; 2010 Jun; 17(6):930-6. PubMed ID: 20410329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel neurotoxoid vaccine prevents mucosal botulism.
    Kobayashi R; Kohda T; Kataoka K; Ihara H; Kozaki S; Pascual DW; Staats HF; Kiyono H; McGhee JR; Fujihashi K
    J Immunol; 2005 Feb; 174(4):2190-5. PubMed ID: 15699151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of new formalin-detoxified botulinum neurotoxin toxoids.
    Keller JE
    Clin Vaccine Immunol; 2008 Sep; 15(9):1374-9. PubMed ID: 18667637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine.
    Lee JC; Hwang HJ; Sakaguchi Y; Yamamoto Y; Arimitsu H; Tsuji T; Watanabe T; Ohyama T; Tsuchiya T; Oguma K
    Microbiol Immunol; 2007; 51(4):445-55. PubMed ID: 17446685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxoid of Clostridium botulinum type F: purification and immunogenicity studies.
    Hatheway CL
    Appl Environ Microbiol; 1976 Feb; 31(2):234-42. PubMed ID: 793522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.
    Ghose C; Kalsy A; Sheikh A; Rollenhagen J; John M; Young J; Rollins SM; Qadri F; Calderwood SB; Kelly CP; Ryan ET
    Infect Immun; 2007 Jun; 75(6):2826-32. PubMed ID: 17371854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, C1, D, and E toxins and tetanus toxin.
    Tsuzuki K; Yokosawa N; Syuto B; Ohishi I; Fujii N; Kimura K; Oguma K
    Infect Immun; 1988 Apr; 56(4):898-902. PubMed ID: 2450068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.
    Clayton MA; Clayton JM; Brown DR; Middlebrook JL
    Infect Immun; 1995 Jul; 63(7):2738-42. PubMed ID: 7790092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved method for development of toxoid vaccines and antitoxins.
    Jones RG; Liu Y; Rigsby P; Sesardic D
    J Immunol Methods; 2008 Aug; 337(1):42-8. PubMed ID: 18571196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic similarity of toxins produced by Clostridium botulinum type C and D strains.
    Oguma K; Syuto B; Iida H; Kubo S
    Infect Immun; 1980 Dec; 30(3):656-60. PubMed ID: 6785231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics study of immunological response to Clostridium botulinum toxin.
    Dezfulian M; Bitar RA; Bartlett JG
    J Clin Microbiol; 1987 Jul; 25(7):1336-7. PubMed ID: 3301895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relation between toxicity and toxin-related-antigen contents of Clostridium botulinum types C and D cultures as determined by mouse bioassay and ELISA.
    Notermans S; Dufrenne J; Kozaki S
    Jpn J Med Sci Biol; 1982; 35(5-6):203-11. PubMed ID: 6761472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin.
    Fujinaga Y; Inoue K; Watanabe S; Yokota K; Hirai Y; Nagamachi E; Oguma K
    Microbiology (Reading); 1997 Dec; 143 ( Pt 12)():3841-3847. PubMed ID: 9421908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of an immune response by oral administration of recombinant botulinum toxin.
    Kiyatkin N; Maksymowych AB; Simpson LL
    Infect Immun; 1997 Nov; 65(11):4586-91. PubMed ID: 9353037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homogeneity and heterogeneity of toxins produced by Clostridium botulinum type C and D strains.
    Oguma K; Syuto B; Agui T; Iida H; Kubo S
    Infect Immun; 1981 Nov; 34(2):382-8. PubMed ID: 6171518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid.
    Siegel LS
    J Clin Microbiol; 1989 Aug; 27(8):1906-8. PubMed ID: 2768475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral responses in cattle to commercial vaccines containing Clostridium perfringens epsilon toxoid and C. botulinum types C and D toxoids last less than a-year.
    Augusto de Oliveira C; Duarte MC; Antunes de Assis R; Alves GG; Silva ROS; Faria Lobato FC
    Anaerobe; 2019 Oct; 59():72-75. PubMed ID: 31129336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.